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Objectives: Venous thromboembolism (VTE) is a frequent but preventable compli-
cation in hospitalized patients. The objective of this population-based simulation 
was to estimate, for Saudi Arabia and using a British (NICE) model, the cost-effi-
ciency of partial versus complete thromboprophylaxis of hospitalized adult patients 
at medium-to-very-high (M2VH) -VTE risk. MethOds: Simulation including all 2012 
Saudi adult medical (n= 2,129,866) and surgical (n= 964,033) hospital admissions, 
expressed in Saudi riyals (SAR), using three scenarios based on published real-
world thromboprophylaxis studies: (1) international study and (2) Saudi subsample 
thereof (Cohen et al, Lancet 2008), and (3) Middle-Eastern study (Mokhtari et al, J 
Thromb Haemost 2011). Variables included rates for: high bleeding risk (mechanical 
versus pharmacoprophylaxis); major bleeding episode (MBE) secondary to pharma-
coprophylaxis; deep vein thrombosis (DVT; pulmonary embolism (PE); and 12-month 
DVT/PE readmission following such discharge diagnosis. Costs considered were: 
thromboprophylaxis; management of MBE, DVT, PE; and 12-month DVT/PE read-
mission. Results: Scenario (1): total costs for partial and complete prophylaxis 
were SAR631,462,830 and SAR508,957,517 for a complete-over-partial cost-avoidance 
by 24.1% of SAR122,505,313/year (SAR92.14 per patient and SAR167.83 per patient 
at VTE risk). Scenario (2): total costs for partial and complete prophylaxis were 
SAR712,441,824 and SAR600,483,584 for a complete-over-partial cost-avoidance 
by 18.6% of SAR111,958,239/year (SAR77.35 per patient and SAR127.58 per patient 
at VTE risk). Scenario (3): total costs for partial and complete prophylaxis were 
SAR749,939,936 and SAR647,300,590 for a complete-over-partial cost-avoidance by 
15.9% of SAR102,639,346/year (SAR62.77 per patient and SAR97.84 per patient at VTE 
risk). cOnclusiOns: In this population-based cost-efficiency simulation for Saudi 
Arabia, thromboprophylaxis of all admitted M2VH-VTE risk versus partial methods 
is associated with significant cost savings per year. Considering the associated 
reductions in DVT, PE, and readmissions, even under increased pharmacoprophy-
laxis-related MBE risk and costs, complete thromboprophylaxis of (M2VH) -VTE risk 
patients achieves the Institute for Healthcare Improvement Triple Aim of better care, 
better patient outcomes, and reduced costs.
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Objectives: Approximately 15-35% of patients with hemophilia A develop inhibi-
tory antibodies to factor VIII. There are currently two bypassing agents to treat 
inhibitor patients in the case of bleeding episodes (BE) and preemptively before 
and during major surgeries. Both APCC and rFVIIa demonstrated similar efficacy 
and safety results. Our aim was to compare the costs of bypass strategy based on 
APCC or rFVIIa while we included only drug acquisition costs, and from them we 
derived costs of bleeding episodes and surgery costs in Hungary, Slovakia, Slovenia 
and Serbia. MethOds: For the purpose of cost comparison, we developed a model 
using cost-minimization approach which included only the costs of APCC or rFVIIa. 
We assessed the cost differences for two basic scenarios - patients with bleeding 
episodes and patients undergoing major surgeries. The doses used in model were: 
i) BE APCC 62.5 U/kg, ii) surgery APCC 85 U/kg, iii) BE and surgery rFVIIa 90 μ g/kg. 
The doses are based on the SmPCs (middle of given dose intervals) and published 
literature (in the case of APCC used in surgery which is administered in higher doses 
in clinical practice compared to declaration in SmPC). Results: In the scenario 
of bleeding episodes, the use of APCC instead of rFVIIa brings the potential sav-
ings € 4,596-8,704; € 5,135-9,347; € 5,738-10,807; € 4,369-8,527 respectively in Hungary, 
Slovakia, Slovenia and Serbia (depending on the dosing scheme). While using APCC 
during major surgeries, the savings are equal to € 157,159 (if compared to rFVIIa 
therapy) and € 15,616 (if compared to the combination therapy of APCC and rFVIIa) 
in Hungary; € 180,653 and € 16,558 in Slovakia; € 196,965 and € 19,362 in Slovenia; 
and € 145,979 and € 15,422 in Serbia. cOnclusiOns: The potential savings by using 
APCC instead of rFVIIa are significant for health care systems, APCC thus indirectly 
enables more treated patients for the same health care costs consumption.
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Objectives: Perform a full economic evaluation of cost minimization of the use 
of Methadone versus oxycodone (extended release), buprenorphine (transdermal 
patches), fentanyl (transdermal patches) and hydromorphone in opioid rotation 
for patients with acute severe pain secondary to cancer and chronic type as rota-
tion option in Mexico, from the point of view of public health. MethOds: A sys-
tematic literature review was conducted to identify articles and extract data of 
safety and efficacy and compare the available alternatives: methadone, oxycodone, 
buprenorphine (PT), fentanyl (PT) and hydromorphone. Based on the results of this 
systematic review was identified that 5 alternatives presented safety and efficacy 
profiles without significant differences. Economic evaluation corresponded to a 
cost minimization, the analysis was performed with three subgroups with rotation 
of opioids, each subgroup received a certain amount of morphine (80mg, 160mg, 
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Objectives: To assess the incremental cost-utility ratio (ICUR) of bosutinib for CML 
as a third-line (3L) treatment for chronic phase (CP) Philadelphia chromosome-
positive (Ph+) patients in Portugal compared to hydroxycarbamide, in the societal 
perspective. MethOds: A survival analysis model was adapted to the Portuguese 
setting. Bosutinib overall survival was based on Study 200, an open-label phase I/
II single-arm study of Ph+ CML patients. Overall survival with hydroxycarbamide 
and time spent in the accelerated and blastic phases, that are assumed to be inde-
pendent of treatment, were estimated by an expert panel of five Portuguese hae-
matologists. Resource consumption was elicited by this expert panel, being unit 
costs based on Portuguese official sources. Utility values were adapted from the IRIS 
study. A 5% discount rate was applied to both costs and consequences on a 50-year 
time horizon. Results: The use of bosutinib allows an increase of 4.1 life years 
(LY) and 3.5 quality adjusted life years (QALY), being associated to an additional 
cost of 88,319€ . Consequently, cost per LY is 21,465€ and cost per QALY is 25,252€ . 
Sensitivity analysis shows that results are mainly driven by survival time gained 
with bosutinib. cOnclusiOns: Bosutinib for CML 3L treatment for CP patients 
in Portugal represents a substantial added benefit relative to hydroxycarbamide 
although with added costs per LY and per QALY. These ratios are generally accepted 
in Portugal, both below 30,000€ willingness to pay threshold.
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Objectives: To assess the cost-effectiveness of romiplostim in the treatment 
of adult patients with ITP in the Czech Republic, in comparison with the medi-
cal standard of care (SoC) and eltrombopag. MethOds: A lifetime treatment 
sequence cost-utility Markov model was developed from the health care payer 
perspective. The model was based on the treatment sequences that reflect cur-
rent practice for ITP management and was driven by platelet response (platelet 
count ≥ 50x109/L), which determined effectiveness and progression along the treat-
ment pathway, need for rescue therapy and risk of bleeding. Costs were derived 
from reimbursement lists available in January 2013. Four scenarios were con-
ducted where romiplostim was compared with SoC with rituximab, SoC without 
rituximab, SoC without both rituximab and mycophenolate mofetil (MMF), and 
eltrombopag. Patients were evaluated by splenectomy status and for the combined 
population (CP). Results: Compared to SoC with rituximab, romiplostim was 
dominant in splenectomised patients and CP, with cost savings of 2,203,982CZK 
and 1,078,899CZK and gains of 1.58 and 1.81 quality-adjusted life-years (QALYs), 
respectively, and was cost-effective in non-splenectomised patients with an ICER 
of 44,107 CZK/QALY. Compared to eltrombopag, romiplostim was dominant in 
splenectomised patients and CP, with cost savings of 1,626,409CZK and 741,613CZK 
and gains of 1.12 and 1.21 QALYs, respectively, and was cost-effective in non-
splenectomised patients with an ICER of 74,266 CZK/QALY. Similar results were 
shown in the other two scenarios: romiplostim was dominant in splenectomised 
patients and CP compared to SoC without rituximab and SoC without both rituxi-
mab and MMF, and was cost-effective in non-splenectomised patients with ICERs 
of 51,011CZK/QALY (SoC without rituximab) and 41,192CZK/QALY (SoC without 
rituximab and MMF). cOnclusiOns: Romiplostim was less costly with higher 
QALY gain compared to SoC and eltrombopag in splenectomised patients and CP. 
Romiplostim was cost-effective with ICERs between 41,000 and 74,000CZK/QALY 
in all non-splenectomised populations in all four scenarios.
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Objectives: To evaluate the cost-effectiveness of celecoxib compared with loxo-
profen for the treatment of patients with chronic pain caused by osteoarthritis, 
rheumatoid arthritis and low back pain in Japan. MethOds: Using the Markov 
model, long-term simulations were conducted with a 3-month Markov cycle for 
each regimen of celecoxib vs. loxoprofen in the perspective of Japanese health 
care payers. The direct medical costs and quality-adjusted life years (QALYs) were 
estimated as outcome measures throughout the lifetime of patients. The base 
case population was aged 57 years which was the weighted mean age from the 
cited literature. All the costs were expressed as of March 2014, and annual dis-
count rates of 2% were applied for both costs and health benefits. Results: The 
incremental effectiveness of celecoxib compared with loxoprofen was 0.024 QALY 
while the incremental cost was JPY 73,785 (USD 716, USD 1 = JPY 103), indicating 
the incremental cost-effectiveness ratio (ICER) was JPY 3,131,480 (USD 30,403) per 
QALY gained. Sensitivity analyses identified two factors substantially sensitive to 
ICER: 1) decrease in efficacy of celecoxib in the recurrence of symptomatic ulcer, 
and 2) increase in utility of the primary disease that causes chronic pain while the 
administration of the drug halts. The literature review, however, supported that 
both of those sensitive cases are not so much likely to happen. cOnclusiOns: 
Celecoxib was considered cost-effective compared with loxoprofen in patients 
with chronic pain in Japan.
